慢性肾脏病中的认知障碍:病理生理、管理与预防
综述指出CKD患者认知障碍风险显著高于一般人群,低GFR和蛋白尿与认知障碍发生及认知功能较差相关,脑血管病可能是主要病理基础,控制血压和减少蛋白尿可能 modestly 减缓认知下降,肾移植可能改善认知功能,管理需综合计划。
要点
- CKD患者认知障碍风险显著增加,低GFR和蛋白尿是相关因素。
- 脑血管病可能是主要病理机制,尿毒症毒素清除受损等也可能参与。
- 控制血压和减少蛋白尿可能 modestly 减缓认知下降,肾移植可能改善认知。
核心结论
- CKD患者认知障碍风险显著高于一般人群,低GFR和蛋白尿与认知障碍及较差认知功能相关。
- 脑血管病可能是主要病理基础,但尿毒症代谢物清除受损、抑郁、睡眠障碍、贫血和多药治疗也可能参与。
- 针对CKD,以ACEI或ARB降低血压和减少蛋白尿可能 modestly 减缓认知下降。
- 透析可改善尿毒症相关严重损害,但似乎不影响更细微的慢性认知障碍;肾移植可能改善许多受者的认知功能。
主要发现
- 低GFR和蛋白尿的存在与认知障碍发生及较差认知功能相关。
- CKD个体中血管疾病过多,脑血管病可能是这些关联的主要病理基础。
- 开始透析可改善尿毒症相关严重损害,但似乎不影响更细微的慢性认知障碍。
- 肾移植似乎可改善许多移植受者的认知功能,提示透析方法不能提供与功能性肾脏相同的认知益处。
临床怎么用
- 管理CKD合并认知障碍患者应包括更频繁的随访、家庭参与共同决策、提高依从性的措施(如书面指导和药片计数)以及关注预先指示并强调理解患者生活目标。
局限性
- 改善血管疾病危险因素可能有助于限制认知下降,但缺乏确切数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with chronic kidney disease (CKD) are at substantially higher risk for developing cognitive impairment compared with the general population, and both lower glomerular filtration rate and the presence of albuminuria are associated with the development of cognitive impairment and poorer cognitive function. Given the excess of vascular disease seen in individuals with CKD, cerebrovascular disease is likely the predominant pathology underlying these associations, though impaired clearance of uremic metabolites, depression, sleep disturbance, anemia, and polypharmacy may also contribute. Modification of vascular disease risk factors may be helpful in limiting decline, though definite data are lacking. Specific to CKD, targeting a low blood pressure and reduction in albuminuria with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers may slow cognitive decline, albeit modestly. Initiation of dialysis can improve severe impairment associated with uremia but does not appear to affect more subtle chronic cognitive impairment. In contrast, kidney transplantation appears to lead to improved cognitive function in many transplant recipients, suggesting that dialysis methods do not provide the same cognitive benefits as having a functioning kidney. Management of patients with both CKD and cognitive impairment should include a comprehensive plan including more frequent follow-up visits; involvement of family in shared decision making; measures to improve compliance, such as written instruction and pill counts; and a focus on advance directives in conjunction with an emphasis on understanding an individual patient's life goals. Further research is needed on novel therapies, including innovative dialysis methods, that aim to limit the development of cognitive impairment, slow decline in those with prevalent impairment, and improve cognitive function.
引用
- Drew DA, Weiner DE, Sarnak MJ, et al. Cognitive Impairment in CKD: Pathophysiology, Management, and Prevention. Am J Kidney Dis. 2019. PMID: 31378643. doi:10.1053/j.ajkd.2019.05.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。